Shares of Celyad SA (NASDAQ:CYAD) have received an average broker rating score of 1.67 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. Celyad SA’s rating score has declined by 67% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Analysts have set a 1-year consensus target price of $49.00 for the company and are forecasting that the company will post ($2.02) earnings per share for the current quarter, according to Zacks. Zacks has also given Celyad SA an industry rank of 102 out of 265 based on the ratings given to related companies.

CYAD has been the subject of a number of recent research reports. Piper Jaffray Cos. restated an “overweight” rating and set a $95.00 target price on shares of Celyad SA in a research report on Tuesday, June 7th. Zacks Investment Research upgraded Celyad SA from a “hold” rating to a “buy” rating and set a $56.00 price objective for the company in a report on Wednesday, May 25th.

Shares of Celyad SA (NASDAQ:CYAD) opened at 22.5806 on Monday. The firm’s market capitalization is $210.29 million. Celyad SA has a one year low of $19.81 and a one year high of $59.50. The stock’s 50 day moving average price is $24.02 and its 200 day moving average price is $37.81.

An institutional investor recently raised its position in Celyad SA stock. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Celyad SA (NASDAQ:CYAD) by 24.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,161 shares of the company’s stock after buying an additional 3,426 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.18% of Celyad SA worth $429,000 as of its most recent SEC filing.

Celyad SA Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

5 Day Chart for NASDAQ:CYAD

Get a free copy of the Zacks research report on Celyad SA (CYAD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with Analyst Ratings Network's FREE daily email newsletter.